Nasopharyngeal Carcinoma (NPC)Phase 2NCT07920250
Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal Carcinoma
A Phase 2 study testing Toripalimab (240mg day1, Q3W*3cycle), Cisplatin (80 mg/m2) and Nab-paclitaxel in people with Nasopharyngeal Carcinoma (NPC) and Radiation-induced Oral Mucositis, run by Affiliated Hospital of Guangdong Medical University at 1 site in China.
Trial summary
The goal of this clinical trial is to learn if the balance of omega-6 and omega-3 fats in red blood cells can predict severe mouth sores caused by radiation therapy in people with locally advanced nasopharyngeal carcinoma (a type of head and neck cancer). Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Nasopharyngeal Carcinoma (NPC), Radiation-induced Oral Mucositis, Head and Neck Neoplasms
- What is being tested?
- Toripalimab (240mg day1, Q3W*3cycle), Cisplatin (80 mg/m2) and Nab-paclitaxel
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 210 participants
- Where
- 1 siteChina
- Study dates
- 1 Nov 2024to 1 Jul 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients:
- Newly diagnosed non-keratinizing nasopharyngeal carcinoma, AJCC 9th edition stage II-III.
- Planned chemoimmunotherapy and radiotherapy.
- Age 18-75 years.
- ECOG performance status 0-1.
- Adequate organ function: WBC ≥4.0×10⁹/L, ANC ≥2.0×10⁹/L, Hb ≥90 g/L, Plt ≥100×10⁹/L, albumin ≥35 g/L, bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN, creatinine ≤1.5×ULN, LVEF ≥50%, normal thyroid function, and complete data.
Show all 12Show fewer
- Healthy controls:
- Age 18-75 years.
- Healthy, no malignancy or chronic organ disease.
- No omega-3 supplementation in the past 3 months.
- ECOG 0.
- Complete data and consent.
Who cannot join
- Patients:
- Other malignancies or metastases.
- Severe organ dysfunction or marrow insufficiency.
- HIV or AIDS or active TB.
- Pregnancy or lactation.
- Immunodeficiency or organ transplantation.
Show all 16Show fewer
- Recent immunosuppressant or corticosteroid use (>10 mg/day prednisone equivalent within 4 weeks).
- Prior radical surgery or experimental therapy.
- Inflammatory bowel disease, chronic diarrhea, gastrointestinal perforation or fistula.
- Regular omega-3 supplementation >4 weeks before enrollment.
- Healthy controls:
- Immunodeficiency or transplantation.
- Pregnancy or lactation.
- Active infection.
- Inflammatory bowel disease, chronic diarrhea, gastrointestinal fistula.
- Any lab abnormality deemed unsuitable by the investigator.
Trial locations and contacts
1 site in 1 country.
China1 site
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, 524001
About this study
Official title: Pre-Radiotherapy Erythrocyte Membrane n-6/n-3 Fatty Acid Ratio Predicts Severe Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma: A Prospective, Single-Arm Interventional Study
The goal of this clinical trial is to learn if the balance of omega-6 and omega-3 fats in red blood cells can predict severe mouth sores caused by radiation therapy in people with locally advanced nasopharyngeal carcinoma (a type of head and neck cancer). The main questions it aims to answer are:
How does the n-6/n-3 fat ratio in red blood cells change during treatment?
Read more
Can the n-6/n-3 fat ratio measured before radiation therapy predict which patients will develop severe mouth sores (grade 3 or higher)?
Researchers will compare patients with healthy volunteers at the start of the study to see if their fat profiles and inflammation markers differ.
Participants will:
Receive immunotherapy (toripalimab) combined with chemotherapy (cisplatin and nab-paclitaxel), followed by radiation therapy with toripalimab.
Give blood samples at 7 time points before, during, and after treatment.
Have their mouth sores checked weekly during radiation therapy.
Complete nutritional assessments and questionnaires.
Read the detailed description
Background and rationale. Nasopharyngeal carcinoma (NPC) is endemic in Southeast Asia and southern China, and most patients are diagnosed with locally advanced disease. Standard treatment for locally advanced NPC (LA-NPC) includes induction chemotherapy followed by concurrent chemoradiotherapy. Although effective, this approach causes substantial acute toxicity, and radiation-induced oral mucositis (RIOM) remains the most common severe complication. PD-1 inhibitors have enabled cisplatin-sparing strategies that maintain efficacy while reducing toxicity, but RIOM is still a major clinical challenge. Omega-6 and omega-3 polyunsaturated fatty acids (PUFAs) have opposing roles in inflammation. The erythrocyte membrane n-6/n-3 PUFA ratio reflects systemic fatty acid balance and inflammatory status over the preceding 2-3 months. This ratio has been linked to chronic disease risk and cancer progression, but its longitudinal changes and relationship with RIOM have not been prospectively examined in LA-NPC patients receiving PD-1 inhibitor-based, cisplatin-sparing regimens.
Study design and setting. This is a prospective, single-center, single-arm interventional study conducted at the Affiliated Hospital of Guangdong Medical University. The study enrolled treatment-naïve patients with LA-NPC (AJCC 9th edition stage II-III) and matched healthy controls. All patients received protocol-directed therapy and were followed prospectively. Healthy controls provided a single blood sample at enrollment. The study was approved by the Ethics Committee of the Affiliated Hospital of Guangdong Medical University (approval no. LY2025-10-025) and conducted in accordance with the Declaration of Helsinki. The study was prospectively registered at ClinicalTrials.gov.
Treatment protocol. All enrolled patients received a three-stage treatment regimen. First, patients received three 21-day cycles of induction chemoimmunotherapy. On day 1 of each cycle, they received intravenous toripalimab 240 mg, cisplatin 80 mg/m², and nab-paclitaxel 260 mg/m². After induction, patients received concurrent toripalimab and intensity-modulated radiotherapy (IMRT). Target volumes included the gross tumor volume of the nasopharynx (GTVnx), gross tumor volume of metastatic lymph nodes (GTVnd), high-risk clinical target volume (CTV1), and low-risk clinical target volume (CTV2). GTVnx and GTVnd received 69.96 Gy, CTV1 received 60 Gy, and CTV2 received 54 Gy, given once daily, five days per week, for 33 fractions. During radiotherapy, patients received three cycles of toripalimab 240 mg every 21 days. After radiotherapy, patients received six 3-weekly cycles of adjuvant toripalimab 240 mg intravenously.
Sample collection and laboratory assessments. Blood samples were collected at seven prespecified time points: T0 (baseline, within 1 week before treatment), T1-T3 (within 3 days after each induction cycle), T4 (pre-radiotherapy, within 1 week before radiotherapy), T5 (mid-radiotherapy, cumulative dose 40 Gy, 19 fractions), T6 (post-radiotherapy, within 3 days after completion), and T7 (1 month after radiotherapy). Healthy controls provided a single sample at enrollment. Erythrocyte membrane fatty acids were quantified by gas chromatography. Individually quantified omega-6 PUFAs were linoleic acid (LA), arachidonic acid (AA), and docosatetraenoic acid (DTA). Individually quantified omega-3 PUFAs were α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Total omega-6 and total omega-3 PUFAs were calculated as the sum of identified fatty acids. The n-6/n-3 ratio was defined as total omega-6 divided by total omega-3 PUFAs. The AA/EPA ratio and n-3 index (EPA + DHA as a percentage of total fatty acids) were also calculated. Plasma cytokines (IL-4, IL-6, IL-10, IL-12p70, IL-17, IFN-γ, and TNF-α) were measured by Luminex multiplex assay. Nutritional assessment included body weight, BMI, white blood cell count, total cholesterol, triglycerides, HDL, LDL, serum albumin, prealbumin, NRS 2002, and PG-SGA.
Data management and statistical analysis. Paper case report forms were double-checked, and two researchers independently entered data into an electronic database, followed by consistency verification and logical validation. A random 20% sample of key indicators was re-tested, and the intraclass correlation coefficient was computed for consistency. For variables with >5% missing data, multiple imputation using chained equations was applied. Statistical analyses were conducted using SPSS version 26.0. Categorical variables are presented as frequencies and percentages. Normally distributed continuous variables are presented as mean ± standard deviation, and non-normally distributed variables as median with interquartile range. Baseline comparisons used chi-square or Fisher's exact test and independent-samples t-test or Mann-Whitney U test. Longitudinal changes were evaluated by repeated-measures analysis of variance, with Greenhouse-Geisser correction when sphericity was violated. Trends in ordinal categorical variables were assessed using Cochran-Armitage and Cochran-Mantel-Haenszel tests. Spearman's rank correlation was used to examine associations between fatty acid parameters and toxicity severity. Univariate logistic regression and receiver operating characteristic (ROC) curve analysis were used to evaluate predictive performance, with the optimal cutoff determined by Youden's index. Calibration was assessed by the Hosmer-Lemeshow test. Because only 22 grade ≥3 RIOM events occurred, multivariable adjustment and internal validation were not performed to avoid overfitting, and predictive performance should be regarded as exploratory.
Sample size and limitations. A total of 105 patients with LA-NPC and 105 healthy controls were enrolled. All patients completed the protocol without loss to follow-up. This single-center, single-arm study in a homogeneous Chinese population may limit generalizability, and the non-randomized design precludes causal inference. The small number of grade ≥3 RIOM events led to wide confidence intervals and precluded extensive multivariable adjustment. No internal or external validation was performed; therefore, the predictive performance should be considered exploratory. Dietary records and dosimetric parameters were not collected. Residual confounding cannot be excluded.
- Being tested
- Toripalimab (240mg day1, Q3W*3cycle), Cisplatin (80 mg/m2), Nab-paclitaxel, Intensity-Modulated Radiotherapy (IMRT)
- Keywords
- Nasopharyngeal Carcinoma, Locally Advanced Nasopharyngeal Carcinoma, Radiation-Induced Oral Mucositis, Oral Mucositis, n-6/n-3 Polyunsaturated Fatty Acid Ratio, n-6/n-3 Fatty Acid Ratio, Erythrocyte Membrane Fatty Acids, Omega-3 Polyunsaturated Fatty Acids, Omega-6 Polyunsaturated Fatty Acids, Predictive Biomarker, Systemic Inflammation, Inflammatory Cytokines
- Medical subject headings
- Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Stomatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Toripalimab (240mg day1, Q3W*3cycle)Biological
PD-1 inhibitor given intravenously at 240 mg on day 1 of each 21-day cycle. It was administered during induction chemoimmunotherapy for 3 cycles, concurrently with radiotherapy for 3 cycles, and as adjuvant therapy for 6 cycles.
Cisplatin (80 mg/m2)Drug
Platinum-based chemotherapy given intravenously at 80 mg/m² on day 1 of each 21-day cycle during induction chemoimmunotherapy for 3 cycles. It was not given concurrently with radiotherapy.
Nab-paclitaxelDrug
Taxane chemotherapy given intravenously at 260 mg/m² on day 1 of each 21-day cycle during induction chemoimmunotherapy for 3 cycles.
Intensity-Modulated Radiotherapy (IMRT)Radiation
External beam radiotherapy delivered with intensity modulation. Target doses were GTVnx and GTVnd 69.96 Gy, CTV1 60 Gy, and CTV2 54 Gy in 33 fractions, once daily, 5 days per week. It was given concurrently with toripalimab and without concurrent cisplatin.
| Study group | Role | What they receive |
|---|---|---|
| Toripalimab with Induction Chemotherapy and Platinum-Free Radiotherapy | Experimental | Participants received protocol-directed three-stage treatment. Stage 1 was induction chemoimmunotherapy with intravenous toripalimab 240 mg, cisplatin 80 mg/m², and nab-paclitaxel 260 mg/m² on day 1 of each 21-day cycle for 3 cycles. Stage 2 was concurrent toripalimab 240 mg every 21 days plus intensity-modulated radiotherapy (IMRT) without concurrent cisplatin. Stage 3 was adjuvant toripalimab 240 mg every 3 weeks for 6 cycles. IMRT target doses were GTVnx/GTVnd 69.96 Gy, CTV1 60 Gy, and CTV2 54 Gy in 33 fractions, once daily, 5 days per week. Blood samples were collected at prespecified time points for erythrocyte fatty acid, cytokine, and nutritional assessments. Receives: Biological: Toripalimab (240mg day1, Q3W*3cycle); Drug: Cisplatin (80 mg/m2); Drug: Nab-paclitaxel; Radiation: Intensity-Modulated Radiotherapy (IMRT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Longitudinal change in erythrocyte membrane n-6/n-3 fatty acid ratio.
Change in erythrocyte membrane n-6/n-3 polyunsaturated fatty acid (PUFA) ratio from baseline to 1 month after radiotherapy.
Measured: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Longitudinal change in erythrocyte membrane ALA level.
Change in erythrocyte membrane alpha-linolenic acid (ALA) level from baseline to 1 month after radiotherapy.
Measured: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Longitudinal change in erythrocyte membrane EPA level.
Change in erythrocyte membrane eicosapentaenoic acid (EPA) level from baseline to 1 month after radiotherapy.
Measured: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Longitudinal change in erythrocyte membrane DHA level.
Change in erythrocyte membrane docosahexaenoic acid (DHA) level from baseline to 1 month after radiotherapy.
Measured: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Longitudinal change in erythrocyte membrane LA level.
Change in erythrocyte membrane linolenic acid (LA) level from baseline to 1 month after radiotherapy.
Measured: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Longitudinal change in erythrocyte membrane AA level.
Change in erythrocyte membrane arachidonic acid (AA) level from baseline to 1 month after radiotherapy.
Measured: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Longitudinal change in erythrocyte membrane DTA level.
Change in erythrocyte membrane docosatetraenoic acid (DTA) level from baseline to 1 month after radiotherapy.
Measured: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Secondary outcomes (7)
Dynamic Changes in IL-4
Changes in plasma levels of interleukin-4 (IL-4) during treatment.
Measured: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-6
Changes in plasma levels of interleukin-6 (IL-6) during treatment.
Measured: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-10
Changes in plasma levels of interleukin-10 (IL-10) during treatment.
Measured: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-12p70
Changes in plasma levels of interleukin-12p70 (IL-12p70) during treatment.
Measured: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-17
Changes in plasma levels of interleukin-17 (IL-17) during treatment.
Measured: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IFN-γ
Changes in plasma levels of interferon-gamma (IFN-γ) during treatment.
Measured: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in TNF-α
Changes in plasma levels of tumor necrosis factor-alpha (TNF-α) during treatment.
Measured: Baseline (T0) to 1 month after radiotherapy (T7).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2026
- Study start1 Nov 2024
- Primary completion1 May 2026
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nasopharyngeal Carcinoma (NPC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single-center, prospective, single-arm interventional study. All enrolled patients with locally advanced nasopharyngeal carcinoma received the same protocol-directed three-stage regimen: induction chemoimmunotherapy with toripalimab, cisplatin, and nab-paclitaxel for 3 cycles; concurrent toripalimab plus intensity-modulated radiotherapy without concurrent cisplatin; and adjuvant toripalimab for 6 cycles. No randomization or masking was used. A separate group of 105 matched healthy controls provided a single baseline blood sample for comparison and did not receive any study intervention.
- Masking
- None (open label)
- Enrolment
- 210 participants (actual)
Sponsor and investigators
- Lead sponsor
- Affiliated Hospital of Guangdong Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Haiqing Luo, Affiliated Hospital of Guangdong Medical University
- Investigators
- Haiqing Luo, Dr., Principal investigator, Affiliated Hospital of Guangdong Medical University, Department of Head and Neck Oncology, Zhanjiang, Guangdong, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07920250
- Sponsor's protocol ID
- LY2025-10-025
- Status last verified
- Oct 2026
- First submitted
- 15 Oct 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying the published results will be made available from the corresponding author upon reasonable request. Data include demographic and clinical characteristics, treatment details, erythrocyte membrane fatty acid profiles, plasma cytokine levels, nutritional parameters, and adverse event data. Requests should be directed to the corresponding author (Haiqing Luo, hqluo@126.com).
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pre-Radiotherapy Erythrocyte Membrane n-6/n-3 Fatty Acid Ratio Predicts Severe Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma: A Prospective, Single-Arm Interventional Study
- ClinicalTrials.gov ID
- NCT07920250
- Acronym / sponsor ID
- LY2025-10-025
- Keywords
- Nasopharyngeal Carcinoma, Locally Advanced Nasopharyngeal Carcinoma, Radiation-Induced Oral Mucositis, Oral Mucositis, n-6/n-3 Polyunsaturated Fatty Acid Ratio, n-6/n-3 Fatty Acid Ratio, Erythrocyte Membrane Fatty Acids, Omega-3 Polyunsaturated Fatty Acids
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 210 participants (actual)
- Lead sponsor
- Affiliated Hospital of Guangdong Medical UniversityUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 May 2026 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 5 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if the balance of omega-6 and omega-3 fats in red blood cells can predict severe mouth sores caused by radiation therapy in people with locally advanced nasopharyngeal carcinoma (a type of head and neck cancer). The main questions it aims to answer are:
How does the n-6/n-3 fat ratio in red blood cells change during treatment?
Can the n-6/n-3 fat ratio measured before radiation therapy predict which patients will develop severe mouth sores (grade 3 or higher)?
Researchers will compare patients with healthy volunteers at the start of the study to see if their fat profiles and inflammation markers differ.
Participants will:
Receive immunotherapy (toripalimab) combined with chemotherapy (cisplatin and nab-paclitaxel), followed by radiation therapy with toripalimab.
Give blood samples at 7 time points before, during, and after treatment.
Have their mouth sores checked weekly during radiation therapy.
Complete nutritional assessments and questionnaires.
Detailed description
Background and rationale. Nasopharyngeal carcinoma (NPC) is endemic in Southeast Asia and southern China, and most patients are diagnosed with locally advanced disease. Standard treatment for locally advanced NPC (LA-NPC) includes induction chemotherapy followed by concurrent chemoradiotherapy. Although effective, this approach causes substantial acute toxicity, and radiation-induced oral mucositis (RIOM) remains the most common severe complication. PD-1 inhibitors have enabled cisplatin-sparing strategies that maintain efficacy while reducing toxicity, but RIOM is still a major clinical challenge. Omega-6 and omega-3 polyunsaturated fatty acids (PUFAs) have opposing roles in inflammation. The erythrocyte membrane n-6/n-3 PUFA ratio reflects systemic fatty acid balance and inflammatory status over the preceding 2-3 months. This ratio has been linked to chronic disease risk and cancer progression, but its longitudinal changes and relationship with RIOM have not been prospectively examined in LA-NPC patients receiving PD-1 inhibitor-based, cisplatin-sparing regimens.
Study design and setting. This is a prospective, single-center, single-arm interventional study conducted at the Affiliated Hospital of Guangdong Medical University. The study enrolled treatment-naïve patients with LA-NPC (AJCC 9th edition stage II-III) and matched healthy controls. All patients received protocol-directed therapy and were followed prospectively. Healthy controls provided a single blood sample at enrollment. The study was approved by the Ethics Committee of the Affiliated Hospital of Guangdong Medical University (approval no. LY2025-10-025) and conducted in accordance with the Declaration of Helsinki. The study was prospectively registered at ClinicalTrials.gov.
Treatment protocol. All enrolled patients received a three-stage treatment regimen. First, patients received three 21-day cycles of induction chemoimmunotherapy. On day 1 of each cycle, they received intravenous toripalimab 240 mg, cisplatin 80 mg/m², and nab-paclitaxel 260 mg/m². After induction, patients received concurrent toripalimab and intensity-modulated radiotherapy (IMRT). Target volumes included the gross tumor volume of the nasopharynx (GTVnx), gross tumor volume of metastatic lymph nodes (GTVnd), high-risk clinical target volume (CTV1), and low-risk clinical target volume (CTV2). GTVnx and GTVnd received 69.96 Gy, CTV1 received 60 Gy, and CTV2 received 54 Gy, given once daily, five days per week, for 33 fractions. During radiotherapy, patients received three cycles of toripalimab 240 mg every 21 days. After radiotherapy, patients received six 3-weekly cycles of adjuvant toripalimab 240 mg intravenously.
Sample collection and laboratory assessments. Blood samples were collected at seven prespecified time points: T0 (baseline, within 1 week before treatment), T1-T3 (within 3 days after each induction cycle), T4 (pre-radiotherapy, within 1 week before radiotherapy), T5 (mid-radiotherapy, cumulative dose 40 Gy, 19 fractions), T6 (post-radiotherapy, within 3 days after completion), and T7 (1 month after radiotherapy). Healthy controls provided a single sample at enrollment. Erythrocyte membrane fatty acids were quantified by gas chromatography. Individually quantified omega-6 PUFAs were linoleic acid (LA), arachidonic acid (AA), and docosatetraenoic acid (DTA). Individually quantified omega-3 PUFAs were α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Total omega-6 and total omega-3 PUFAs were calculated as the sum of identified fatty acids. The n-6/n-3 ratio was defined as total omega-6 divided by total omega-3 PUFAs. The AA/EPA ratio and n-3 index (EPA + DHA as a percentage of total fatty acids) were also calculated. Plasma cytokines (IL-4, IL-6, IL-10, IL-12p70, IL-17, IFN-γ, and TNF-α) were measured by Luminex multiplex assay. Nutritional assessment included body weight, BMI, white blood cell count, total cholesterol, triglycerides, HDL, LDL, serum albumin, prealbumin, NRS 2002, and PG-SGA.
Data management and statistical analysis. Paper case report forms were double-checked, and two researchers independently entered data into an electronic database, followed by consistency verification and logical validation. A random 20% sample of key indicators was re-tested, and the intraclass correlation coefficient was computed for consistency. For variables with >5% missing data, multiple imputation using chained equations was applied. Statistical analyses were conducted using SPSS version 26.0. Categorical variables are presented as frequencies and percentages. Normally distributed continuous variables are presented as mean ± standard deviation, and non-normally distributed variables as median with interquartile range. Baseline comparisons used chi-square or Fisher's exact test and independent-samples t-test or Mann-Whitney U test. Longitudinal changes were evaluated by repeated-measures analysis of variance, with Greenhouse-Geisser correction when sphericity was violated. Trends in ordinal categorical variables were assessed using Cochran-Armitage and Cochran-Mantel-Haenszel tests. Spearman's rank correlation was used to examine associations between fatty acid parameters and toxicity severity. Univariate logistic regression and receiver operating characteristic (ROC) curve analysis were used to evaluate predictive performance, with the optimal cutoff determined by Youden's index. Calibration was assessed by the Hosmer-Lemeshow test. Because only 22 grade ≥3 RIOM events occurred, multivariable adjustment and internal validation were not performed to avoid overfitting, and predictive performance should be regarded as exploratory.
Sample size and limitations. A total of 105 patients with LA-NPC and 105 healthy controls were enrolled. All patients completed the protocol without loss to follow-up. This single-center, single-arm study in a homogeneous Chinese population may limit generalizability, and the non-randomized design precludes causal inference. The small number of grade ≥3 RIOM events led to wide confidence intervals and precluded extensive multivariable adjustment. No internal or external validation was performed; therefore, the predictive performance should be considered exploratory. Dietary records and dosimetric parameters were not collected. Residual confounding cannot be excluded.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single-center, prospective, single-arm interventional study. All enrolled patients with locally advanced nasopharyngeal carcinoma received the same protocol-directed three-stage regimen: induction chemoimmunotherapy with toripalimab, cisplatin, and nab-paclitaxel for 3 cycles; concurrent toripalimab plus intensity-modulated radiotherapy without concurrent cisplatin; and adjuvant toripalimab for 6 cycles. No randomization or masking was used. A separate group of 105 matched healthy controls provided a single baseline blood sample for comparison and did not receive any study intervention.
| Arm | Type | Receives |
|---|---|---|
| Toripalimab with Induction Chemotherapy and Platinum-Free Radiotherapy | Experimental | Biological: Toripalimab (240mg day1, Q3W*3cycle), Drug: Cisplatin (80 mg/m2), Drug: Nab-paclitaxel, Radiation: Intensity-Modulated Radiotherapy (IMRT)Participants received protocol-directed three-stage treatment. Stage 1 was induction chemoimmunotherapy with intravenous toripalimab 240 mg, cisplatin 80 mg/m², and nab-paclitaxel 260 mg/m² on day 1 of each 21-day cycle for 3 cycles. Stage 2 was concurrent toripalimab 240 mg every 21 days plus intensity-modulated radiotherapy (IMRT) without concurrent cisplatin. Stage 3 was adjuvant toripalimab 240 mg every 3 weeks for 6 cycles. IMRT target doses were GTVnx/GTVnd 69.96 Gy, CTV1 60 Gy, and CTV2 54 Gy in 33 fractions, once daily, 5 days per week. Blood samples were collected at prespecified time points for erythrocyte fatty acid, cytokine, and nutritional assessments. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Newly diagnosed non-keratinizing nasopharyngeal carcinoma, AJCC 9th edition stage II-III.
- Planned chemoimmunotherapy and radiotherapy.
- Age 18-75 years.
- ECOG performance status 0-1.
- Adequate organ function: WBC ≥4.0×10⁹/L, ANC ≥2.0×10⁹/L, Hb ≥90 g/L, Plt ≥100×10⁹/L, albumin ≥35 g/L, bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN, creatinine ≤1.5×ULN, LVEF ≥50%, normal thyroid function, and complete data.
Key exclusion criteria (16 listed)
- Other malignancies or metastases.
- Severe organ dysfunction or marrow insufficiency.
- HIV or AIDS or active TB.
- Pregnancy or lactation.
- Immunodeficiency or organ transplantation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Toripalimab (240mg day1, Q3W*3cycle)PD-1 inhibitor given intravenously at 240 mg on day 1 of each 21-day cycle. It was administered during induction chemoimmunotherapy for 3 cycles, concurrently with radiotherapy for 3 cycles, and as adjuvant therapy for 6 cycles. | Biological | Toripalimab with Induction Chemotherapy and Platinum-Free Radiotherapy |
| Cisplatin (80 mg/m2)Platinum-based chemotherapy given intravenously at 80 mg/m² on day 1 of each 21-day cycle during induction chemoimmunotherapy for 3 cycles. It was not given concurrently with radiotherapy. | Drug | Toripalimab with Induction Chemotherapy and Platinum-Free Radiotherapy |
| Nab-paclitaxelTaxane chemotherapy given intravenously at 260 mg/m² on day 1 of each 21-day cycle during induction chemoimmunotherapy for 3 cycles. | Drug | Toripalimab with Induction Chemotherapy and Platinum-Free Radiotherapy |
| Intensity-Modulated Radiotherapy (IMRT)External beam radiotherapy delivered with intensity modulation. Target doses were GTVnx and GTVnd 69.96 Gy, CTV1 60 Gy, and CTV2 54 Gy in 33 fractions, once daily, 5 days per week. It was given concurrently with toripalimab and without concurrent cisplatin. | Radiation | Toripalimab with Induction Chemotherapy and Platinum-Free Radiotherapy |
Primary outcome
Longitudinal change in erythrocyte membrane n-6/n-3 fatty acid ratio.
Time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Change in erythrocyte membrane n-6/n-3 polyunsaturated fatty acid (PUFA) ratio from baseline to 1 month after radiotherapy.
Longitudinal change in erythrocyte membrane ALA level.
Time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Change in erythrocyte membrane alpha-linolenic acid (ALA) level from baseline to 1 month after radiotherapy.
Longitudinal change in erythrocyte membrane EPA level.
Time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Change in erythrocyte membrane eicosapentaenoic acid (EPA) level from baseline to 1 month after radiotherapy.
Longitudinal change in erythrocyte membrane DHA level.
Time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Change in erythrocyte membrane docosahexaenoic acid (DHA) level from baseline to 1 month after radiotherapy.
Longitudinal change in erythrocyte membrane LA level.
Time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Change in erythrocyte membrane linolenic acid (LA) level from baseline to 1 month after radiotherapy.
Longitudinal change in erythrocyte membrane AA level.
Time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Change in erythrocyte membrane arachidonic acid (AA) level from baseline to 1 month after radiotherapy.
Longitudinal change in erythrocyte membrane DTA level.
Time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).
Change in erythrocyte membrane docosatetraenoic acid (DTA) level from baseline to 1 month after radiotherapy.
7 secondary outcomes
Dynamic Changes in IL-4
Time frame: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-6
Time frame: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-10
Time frame: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-12p70
Time frame: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IL-17
Time frame: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in IFN-γ
Time frame: Baseline (T0) to 1 month after radiotherapy (T7).
Dynamic Changes in TNF-α
Time frame: Baseline (T0) to 1 month after radiotherapy (T7).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying the published results will be made available from the corresponding author upon reasonable request. Data include demographic and clinical characteristics, treatment details, erythrocyte membrane fatty acid profiles, plasma cytokine levels, nutritional parameters, and adverse event data. Requests should be directed to the corresponding author (Haiqing Luo, hqluo@126.com).
Related trials for Nasopharyngeal Carcinoma (NPC)
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Not yet recruitingObservational study
Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
Nasopharyngeal Carcinoma (NPC)
Active, not recruitingPhase 2/3
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Haiqing Luo, Dr. principal investigator
Affiliated Hospital of Guangdong Medical University, Department of Head and Neck Oncology, Zhanjiang, Guangdong, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Toripalimab (240mg day1, Q3W*3cycle), Cisplatin (80 mg/m2) and Nab-paclitaxel in people with Nasopharyngeal Carcinoma (NPC) and Radiation-induced Oral Mucositis, run by Affiliated Hospital of Guangdong Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Longitudinal change in erythrocyte membrane n-6/n-3 fatty acid ratio. (time frame: Baseline (within 1 week before treatment) to 1 month after radiotherapy (T7).). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.